Search

An 80-year-old man with pityriasis rubra pilaris (PRP) exhibited lack of efficacy during treatment with guselkumab, methotrexate, secukinumab, upadacitinib, and an unspecified corticosteroid. The man had a history of psoriasis and PRP and had previously been treated with topical corticosteroids, guselkumab, methotrexate, and phototherapy, all of which failed. He was then given secukinumab and upadacitinib, but there was no improvement. Finally, he was given brodalumab, acitretin, and triamcinolone, which resulted in significant improvement and resolution of keratoderma after 3 months. [Extracted from the article]

A 31-year-old woman developed cutaneous atrophy while being treated for alopecia areata with clobetasol and triamcinolone. She had a plaque of erythematous atrophic alopecia on her scalp, and her trichoscopy showed various abnormalities. The woman was diagnosed with cutaneous atrophy secondary to the medications. She underwent treatment with sodium chloride to dissolve corticoid crystals, but it was not effective. Surgical removal of the crystals and subsequent treatment with bleomycin and fluorouracil resulted in complete resolution of the cutaneous atrophy. [Extracted from the article]

This article from Reactions Weekly describes two case reports of patients with ptychotropic porokeratosis (PP) or perianal PP who did not respond to various treatments. The first patient, a 63-year-old man with a history of chronic myeloid leukemia, received photodynamic therapy (PDT) and topical medications such as imiquimod, diclofenac, zinc oxide, tacalcitol, calcipotriol, and calcitriol, but only PDT showed slight improvement. After switching to a cholesterol and simvastatin-based ointment, his condition improved after 26 months. The second patient, a 47-year-old man with perianal PP, also did not respond to PDT and topical medications such as glycolic acid, tretinoin, salicylic acid, diclofenac, and corticosteroids. However, after using the cholesterol and simvastatin-based ointment for 24 months, his condition improved. [Extracted from the article]

In a retrospective study of 8 patients with juvenile localised craniofacial scleroderma (JLCS), one patient exhibited a lack of efficacy during treatment with methotrexate and corticosteroids. Despite receiving this treatment, an MRI showed progression of brain lesions. As a result, the patient was switched to mycophenolate mofetil treatment. [Extracted from the article]

The patients, who had been exposed to colon cleansing solution PEG-3350/sodium-sulfate/sodium-bicarbonate/sodium-chloride/potassium-chloride [Klean-Prep] and PEG 4000 (1 patient); PEG-3350/sodium-chloride/sodium-bicarbonate/potassium-chloride [Endofalk Classic], disinfectant chlorhexidine [Paroex] containing PEG for dental treatment, vaginal application of povidone-iodine solution containing PEG 400 and PEG 4000 (1 patient); SC injection of depot contraceptive medroxyprogesterone acetate [Sayana] containing PEG 3350 (1 patient); depot contraceptive medroxyprogesterone [Depot-clinovir] contains PEG 3350 (1 patient); prednisolone injection [Rotexmedica] contains PEG 4000; oral analgesic metamizole [Novalminsulfon Lichtenstein] contains PEG 6000 and effervescent calcium tablet [Calcium Sandoz forte] containing PEG 4000 (1 patient); different oral analgesics paracetamol, ibuprofen and unspecified NSAIDs (ASS) (1 patient); cough lozenge ambroxol [Mucoangin] contains PEG 6000 and cefalexin [cephalexin] contains PEG 6000, metamizole [Novalgin] contains PEG 4000 and PEG 8000 (1 patient); erythromycin syrup [Infectomycin], contains PEG 6000 (1 patient); colon cleansing solution PEG-3350/sodium-chloride/sodium-sulfate/potassium-chloride/ascorbic-acid [Moviprep Orange] and unspecified corticosteroid and local anaesthetic injection lidocaine/triamcinolone and PEG (1 patient); local anesthetic injection mepivacaine, contains PEG and colon cleansing solution PEG 3350 [Movicol] and iodine [iodide] solution containing PEG (1 patient). [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 59-year-old woman exhibited lack of efficacy during treatment with methotrexate and unspecified corticosteroids for psoriasis vulgaris and psoriatic arthritis [ I route and dosage not stated i ]. Subsequently, she was admitted due to erythematous papular skin lesions and exacerbation of psoriasis arthritis. she was found to have hypertension, obesity and nodular goiter of the thyroid. On physical investigation revealed that her recurrent skin lesions did not improvement after treatment with topical unspecified corticosteroids and methotrexate from the previous 2 years. [Extracted from the article]

Reports on cases of side effects of various drugs. Intestinal pseudo-obstruction treated with antineoplastic agent, distigmine bromide; Toxicities associated with lozapine; Myoclonus induced by cotrimoxazole.

She started receiving bilastine, topical clobetasol [Dermovate] ointment, unspecified systemic corticosteroids and emollients. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 34-year-old woman experienced inefficacy during treatment with bilastine, clobetasol and unspecified corticosteroids for pemphigoid gestationis (PG) during pregnancy [ I not all routes and dosages stated i ]. As a result, IV immune globulin was added to the conventional treatment, with a favourable outcome. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 60-year-old man experienced rebound bullous pemphigoid following discontinuation of prednisone and unspecified corticosteroids treatment. A punch biopsy with immunofluorescence revealed eosinophilic spongiosis and linear basement membrane zone staining consistent with bullous pemphigoid. Based on these findings, the worsening rash was diagnosed as a rebound bullous pemphigoid following discontinuation of prednisone and unspecified corticosteroids. [Extracted from the article]

Laboratory investigation revealed plasma total testosterone < 10 ng/dL, serum LH < 0.1 mIU/mL and beta-human chorionic gonadotropin < 0.1 mIU/mL. At 14 months of age, a leuprolide stimulation test showed peak serum luteinizing hormone (LH) of 1.41 mIU/mL and peak plasma total testosterone of 21 ng/dL. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 4-month old boy developed central precocious puberty (CPP) following accidental exposure to testosterone. [Extracted from the article]

Therefore, the woman's thalidomide therapy was stopped and her further investigation revealed thrombocytopenia with platelet count of 4000 /cumm and abnormal coagulation parameters with elevated prothrombin time and decreased aPTT. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 39-year-old woman exhibited lack of efficacy during treatment with hydroxychloroquine and unspecified corticosteroids for chronic cutaneous lupus erythematosus, and developed thrombocytopenia during treatment with thalidomide for chronic cutaneous lupus erythematosus [ I not all routes and dosages stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 57-year-old man exhibited a lack of efficacy with bexarotene and unspecified corticosteroids, while being treated for human T-cell lymphotropic virus (HTLV) type-I associated adult T-cell leukemia/lymphoma (ATLL). Previously, he had received treatment with unspecified corticosteroids and antibiotics. Human t-cell lymphotropic virus (htlv) type-1-associated adult t-cell leukemia/lymphoma (atll) presenting with diffuse lichen nitidus-like rash. [Extracted from the article]

High cumulative doses of potent/very potent topical corticosteroids (TCSs) are associated with an increased risk of osteoporosis or major osteoporotic fracture (MOS), according to study results reported in I JAMA Dermatology i . For osteoporosis, the incidence rate for 200g-499g of TCSs was 36.7 per 10 000 person-years (PY). Compared with exposure to 200-499g of TCSs, the population-attributable risk with higher doses was 4.3% for osteoporosis, 2.7% for MOF, 2.2% for vertebral fractures and 2.2% for use of osteoporosis medication. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event The male neonate was born with adrenal hyperplasia, genital undervirilisation (micropenis, chordee, perineoscrotal hypospadias and bifid scrotum) and adrenal steroid abnormalities following in-utero exposure to neomycin/polymixin-B/nystatin [ I not all outcomes stated; duration of treatment to reactions onsets not stated i ]. The mother had vaginal discharge starting from the 8th week of gestation for which she had received vaginal neomycin/polymixin-B/nystatin [Polygynax] capsules comprising nystatin 100000IU, neomycin [neomycin sulfate] 35000IU and polymixin-B 35000IU. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug interaction A 57-year-old woman developed hypotonic hyponatremia and hyperkalemic renal tubular acidosis following concomitant administration of cotrimoxazole and telmisartan [ I duration of treatments to reaction onsets and routes not stated i ]. The woman had history of aquaporin-4 (AQP4) antibody-positive optic neuritis (since last two years), hypertension and diabetes mellitus (diagnosed at the age of 47 years), diabetic polyneuropathy and proliferative diabetic retinopathy. Hyponatremia associated with prophylactic low-dose trimethoprim during systemic corticosteroid therapy for aqp4-positive optic neuritis in a diabetic patient. [Extracted from the article]

Patient 1: An adult patient, who was diagnosed with glioma, started receiving dexamethasone [Decadron] >8mg daily and radiation therapy at 60Gy. Patient 2: An adult patient, who was diagnosed with glioma, started receiving treatment with dexamethasone [Decadron] >8mg and radiation therapy at 60Gy. Patient 10: An adult patient, who was diagnosed with glioma, started receiving dexamethasone [Decadron] >8mg daily and radiation therapy at 60Gy. [Extracted from the article]

Laboratory investigation revealed low levels of serum sodium, serum glucose, free T4 and elevated levels of potassium and TSH. Upon follow-up, approximately one year after her last dose of pembrolizumab, she was found to be stable on treatment with insulin, cortisone and levothyroxine sodium. Subsequently, HLA class II allele typing displayed HLA-DRB1*04.16, DQB1*02.05 and DQA1*01.03 allotypes. [Extracted from the article]

A female neonate [ I exact age at reaction onset not stated i ] developed increased serum levels of -glutamyltransferase (GGT) during treatment with ketoconazole for hypercortisolism. However, the serum levels of GGT increased from 93 to 324 U/L [ I duration of treatment to reaction onset not stated i ], while other parameters of liver toxicity were decreasing. B Author comment: b I "An attempt was made to decrease the adrenal cortisol production by blocking adrenal steroid synthesis with ketoconazole (1.0mg twice a day). [Extracted from the article]

The article presents a case study of a 70-year-old man who developed acquired resistance to ceftazidime during treatment for Klebsiella pneumoniae infection and eventually died. The man was admitted with acute pulmonary oedema and generalised anasarca to the central intensive care unit in Albania in May 2018. He started receiving conservatory treatment with IV ceftazidime and non-invasive ventilation, corticosteroids, anticoagulants and unspecified diuretics.

The article presents a case study of a 12-year-old male patient who developed exacerbation of respiratory disease during treatment with ibuprofen for uncontrolled asthma, and local oedema at injection site during treatment with mepolizumab for uncontrolled asthma. Other medical information about the patient, who had a history of poorly controlled asthma and is positive for oral challenge test with aspirin for suspected aspirin-exacerbated respiratory disease, is presented.

The article presents a case study of a 56 year old man who developed fatal Strongylodiasis hyperinfection syndrome and Enterococcus faecium infection following corticosteroid therapy with prednisone, prednisolone and methylprednisolone.

The article presents a case study of a 4-year-old girl, who developed increased body weight and corticosteroid dependence during treatment with deflazacort, methylprednisolone, tetracosactide and prednisone.

The article reports on the study reported in "Clinical Drug Investigation" which found that the risk of tendon rupture with fluoroquinolones depends on timing, concomitant exposure to oral corticosteroids, and cumulative dose.

The article presents three case studies of patients who developed an acute liver injury after the treatment with methylprednisolone, vitamin D or dexamethasone and alemtuzumab . Topics mention including the pulse corticosteroid therapy, subsequent blood testing and synergistic hepatoxic effect of the methylprednisolone with interferon beta.

The article presents a case study of a patient who developed folliculitis after receiving treatment with desoximetasone for scalp psoriasis in an open-label, observational study that included 20 patients.